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Abstract
Background: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations
associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and
their nanometer-scale sizes may allow for passive accumulation in solid tumors. As a first step towards the goal of
extravascular cell permeabilization, we aim to characterize the sonoporation potential of a low-boiling point
formulation of PCCAs in vitro.
Methods: Parameters to induce acoustic droplet vaporization and subsequent microbubble cavitation were
optimized in vitro using high-speed optical microscopy. Sonoporation of pancreatic cancer cells in suspension was
then characterized at a range of pressures (125–600 kPa) and pulse lengths (5–50 cycles) using propidium iodide as
an indicator molecule.
Results: We achieved sonoporation efficiencies ranging from 8 ± 1% to 36 ± 4% (percent of viable cells), as
evidenced by flow cytometry. Increasing sonoporation efficiency trended with increasing pulse length and peak
negative pressure.
Conclusions: We conclude that PCCAs can be used to induce the sonoporation of cells in vitro, and our results
warrant further investigation into the use of PCCAs as extravascular sonoporation agents in vivo.
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Background
Sonoporation refers to the process by which ultrasound-
stimulated microbubbles are used to permeabilize cell
membranes and enhance the intracellular accumulation
of drugs, genes, or indicator dyes [1, 2]. This holds po-
tential as a physical targeting method to drive drug de-
livery non-invasively and with high spatial specificity.
However, inherent limitations associated with microbub-
ble contrast agents used for previous in vitro inves-
tigations [3–7] must be overcome to enable in vivo
translation and subsequent widespread utility of this
technique.
First, microbubbles are relatively large (1–10 μm) and
therefore cannot escape the vasculature following intra-
venous administration [8]. This can be useful for some
applications including drug or gene delivery to vascular
endothelial cells [9] and ultrasound-mediated disruption
of endothelial tight junctions to open the blood-brain
barrier [10, 11]. However, extravascular sonoporation for
the purpose of improved drug or gene delivery within a tar-
get tissue is not feasible. Second, microbubbles have limited
persistence in circulation (<10 min) [8]. This necessitates
continuous infusion or repeat bolus injections in situations
where repeat or long duration treatment is required.
Phase-change ultrasound contrast agents (PCCAs) are
nanometer scale, liquid-filled droplets that can be
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vaporized into microbubbles when subjected to ultra-
sound of sufficient amplitude through a process termed
acoustic droplet vaporization (ADV). These agents are
characterized by longer circulation half-lives than
similarly formulated microbubbles [12, 13], and their
nanometer-scale size distributions may allow for passive
accumulation in leaky tumors via the enhanced perme-
ability and retention (EPR) effect [13, 14]. Furthermore,
since PCCAs are nearly invisible to ultrasound in their
liquid state, high concentrations can be used without the
shielding effect characteristic of high microbubble con-
centrations. PCCA-derived microbubbles destroyed in
one acoustic pulse may be replenished through subse-
quent vaporization events, thereby allowing for the sus-
tained generation of cavitation energy and enhanced
sonoporation [15]. PCCAs therefore offer a solution to
the major limitations previously given for microbubble-
mediated sonoporation and hold the potential for extra-
vascular sonoporation in vivo.
PCCA formulations are commonly filled with perfluor-
ocarbons with boiling points near body temperature,
such as dodecafluoropentane (DDFP, bp = 29 °C), and a
few laboratories have demonstrated the sonoporation
potential of such agents in vitro [15–18]. While these
initial studies show promise, the high negative pressures
required to vaporize nanoscale DDFP-filled PCCAs
(3–6 MPa [14, 15]) may cause unwanted bioeffects such
as heating or cell lysis in an in vivo setting. Our laboratory
has developed a class of low-boiling point PCCAs filled
with octofluoropropane (OFP, bp = −36.7 °C), which are
characterized by far lower pressure requirements for
vaporization when compared to DDFP-filled PCCAs
(~20× lower). Therefore, we hypothesize that our formula-
tion will offer greater control over the bioeffects caused by
ADV and subsequent microbubble cavitation. The primary
objective of this study is to characterize the sonoporation
potential of these low-boiling point PCCAs in vitro.
The precise mechanisms involved in PCCA-mediated
sonoporation remain unknown, and likely depend on a
number of factors including the contrast agent formula-
tion, specific acoustic parameters (frequency, peak nega-
tive pressure [3], duty cycle, etc.), and non-acoustic
parameters (microbubble size and bubble-to-cell dis-
tance [19], cell culture conditions, size of sonoporation
indicator [3], etc.). It is conceivable that PCCA-induced
sonoporation is driven by the same mechanisms that
mediate microbubble sonoporation, with membrane
permeabilization being a product of microbubble cavita-
tion following ADV. However, the rapid expansion of an
individual droplet as it phase-converts into a microbub-
ble may itself influence cell permeability. A secondary
objective of this study is to determine if the vaporization
event of low-boiling point PCCAs contributes to sono-
poration and/or effects cell viability.
Methods
Fabrication and characterization of phase-change
ultrasound contrast agents
Low-boiling point PCCAs containing liquid octa-
fluoropropane (OFP, boiling point −36.7 °C) were
generated as described elsewhere [20]. First, lipid-
shelled, OFP-filled microbubbles were prepared. Briefly,
90 mol% 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
and 10 mol% 1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine-N-methoxy(polyethylene-glycol)-2000 (DSPE-
PEG2000) (Avanti Polar Lipids, Alabaster, AL, USA)
were combined and dissolved in a phosphate-buffered
saline (PBS)-based solution containing 15% propylene
glycol (v/v) and 5% glycerol (v/v) for a final lipid con-
centration of 1.0 mg/mL. This lipid solution (1.5 mL)
was aliquoted into 3.0 mL glass vials and the headspace
air was exchanged with OFP gas (FluoroMed, Round
Rock, TX, USA). Finally, microbubbles were generated
by vigorous shaking of the lipid vials using a VialMix
(Bristol-Myers-Squibb, New York, NY, USA).
The OFP microbubbles were condensed into liquid-
filled nanodroplets (i.e., PCCAs) [20]. Microbubble vials
were cooled in an isopropanol/CO2 bath maintained be-
tween −10 and −13 °C. Simultaneously, the headspace
pressure of the vials was gradually increased through the
addition of excess OFP gas until microbubble condensa-
tion was observed. Phase transition is visually apparent,
as the initially opaque microbubble solution turns trans-
lucent when condensed into liquid-filled particles.
The size distribution and concentration of the PCCAs
were characterized using a NanoSight NS500 (Malvern
Instruments, Westborough, MA, USA) capable of de-
tecting nanoparticles between 50 and 2000 nm. PCCAs
were diluted 3000-fold in HPLC-grade, 20 nm filtered
water. Four, 30-s recordings were captured per sample
to calculate an average size distribution and concentra-
tion for each sample. This procedure was repeated in trip-
licate for three separate vials of PCCAs and averaged to
get a representative size distribution and concentration.
The particles were characterized by a polydisperse size
distribution, as in Fig. 1, with a mean size of 143 ± 13 nm
and concentration of 1.7 ± 0.1 × 1012 particles/mL (see
Additional file 1 for error estimation).
Visualization of PCCA vaporization and secondary
microbubble affects using optical microscopy and
high-speed photography
High-speed optical microscopy was used to detect
PCCA vaporization following ultrasound stimulation
using a previously described experimental setup [21, 22].
Briefly, an inverted microscope with a 100× water
immersion objective (Olympus IX71, Center Valley, PA,
USA) was interfaced with a high-speed camera (FastCam
SA1.1, Photron USA, Inc., San Diego, CA, USA). The
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objective was submerged in a temperature-controlled
water bath fixed on top of the microscope. The water
bath was filled with degassed water and held at 37 °C. A
solution of PCCAs diluted in PBS (6.7% v/v) was
injected into a microcellulose tube (200-μm inner
diameter) (Spectrum Labs, Inc., Rancho Dominguez,
CA, USA) positioned over the optical focus. This injec-
tion was followed by a brief waiting period to allow the
flowing particles to become nearly stationary. This en-
abled clear visualization of vaporization events as images
become blurred when particles are flowing.
A 1.0-MHz spherically focused piston transducer
(diameter = 19 mm, focal distance = 38 mm, IL0106HP,
Valpey Fisher Corp., Hopkinton, MA, USA) was sub-
merged in the water bath and positioned such that the
acoustic focus was aligned with the microcellulose tube
at the optical focus as described previously [22]. Briefly,
a calibrated needle hydrophone (HNA-0400, Onda
Corp., Sunnyvale, CA, USA) was aligned with the micro-
scope focus and used to subsequently align the focus of
the transducer to that location. The hydrophone was
then used to calibrate the pressure output of the trans-
ducer at various excitation voltages. The transducer was
excited with sinusoidal pulses generated with an arbi-
trary waveform generator (AFG3021C, Tektronix, Inc.,
Beaverton, OR, USA) and amplified approximately
60 dB with a power amplifier (A500, ENI, Rochester, NY,
USA). Following calibration, the hydrophone was re-
placed with a microcellulose tube, which was aligned
with the microscope focus. In this way, we ensured that
the plane of the tube visible in the optical focus was sub-
jected to the calibrated acoustic pressures aligned to that
location.
PCCAs flowing through the microcellulose tube were
exposed to acoustic pulses with lengths of 5, 10, 20, and
50 cycles and peak negative pressures of 125, 300, 600,
1000, and 2000 kPa to observe the effect of pulse length
and pressure on PCCA vaporization. In subsequent ex-
periments, pre-vaporized PCCAs were stimulated with a
second identical acoustic pulse to observe how ultra-
sound affected the generated microbubbles.
A synchronization pulse from the waveform generator
was used to trigger the high-speed camera. Video
recordings were set to begin just before the manually
triggered ultrasound pulse such that vaporization or
microbubble manipulations would be recorded in their
entirety. A frame rate of 500 frames per second was
employed. Images and videos were stored on a computer
using proprietary camera software (PFV; Photron USA,
Inc., San Diego, CA, USA) and analyzed using ImageJ
(NIH, Bethesda, MD, USA).
Detection of cavitation signals following PCCA
vaporization
Similar to the high-speed microscopy experiments,
PCCA solutions were perfused through a microcellulose
tube (200 μL/min) aligned with the focus of a 1.0-MHz
piston transducer. The transducer was calibrated at the
focus using a needle hydrophone, and PCCAs were acti-
vated with sinusoidal ultrasound pulses using a pulse
repetition frequency (PRF) of 5.0 Hz, peak negative pres-
sures ranging from 125 to 2000 kPa, and pulse lengths
between 5 and 50 cycles. Three concentrations of
PCCAs were tested: 0.067, 0.67, and 6.7% (v/v) in PBS.
All conditions and concentrations were tested in tripli-
cate using three independent vials of PCCAs. Control
trials with a water-filled tube were used as a reference to
estimate stable and inertial cavitation generated by the
vaporized PCCAs.
To detect cavitation signals, a separate, spherically
focused receive transducer (7.5 MHz center frequency,
diameter = 19 mm, focal distance = 50 mm) (V321,
Panametrics, Inc., Waltham, MA, USA) was positioned
perpendicular to the transmit transducer such that the
microcellulose tube was aligned with both transducer
foci. Signals from the receive transducer were acquired
using a 14-bit analog to digital conversion (ADC) card
with a sampling frequency of 100 MHz (PDA14, Signatec,
Corona, CA, USA) installed in a computer (Dell, Round
Rock, TX, USA) running a custom acquisition program
(LabVIEW, National Instruments Corp., Austin, TX,
USA). A total of 50 individual signals were captured for
each combination of pressure, pulse length, and PCCA
concentration. These signals were saved and post-
processed using MATLAB (MathWorks Inc., Natick, MA,
USA).
A custom MATLAB script was developed to quantify
the energy of stable and inertial cavitation generated for
each condition. First, a window from 50–110 μs refer-
enced to the beginning of the acoustic pulse was applied
Fig. 1 Nanosight results for OFP-filled PCCAs (N = 3 vials). The mean
particle size (±SD) was found to be 140 ± 10 nm and the average
concentration (±SD) was 1.7 ± 0.1 × 1012 particles/mL
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to select the signal emitted by the PCCAs. The 50 indi-
vidual RF signals from each exposure condition were
converted into the frequency domain. Detection of the
second harmonic component was used to estimate the
stable cavitation level by filtering the data from 1.8 to
2.2 MHz (Butterworth filter, order 3). The broadband
signal resulting from inertial cavitation was detected by
filtering the signals from 5.25 to 7.75 MHz (Butterworth
filter, order 3) and by simultaneously excluding the har-
monic components at 6 and 7 MHz. Finally, energies of
these stable and inertial cavitation signals were calcu-
lated, averaged among the 50 individual signals for each
condition, and normalized by the energy calculated for a
water-filled tube exposed to the same acoustic condi-
tions. This procedure was repeated for three independ-
ent vials of PCCAs. The average, normalized cavitation
energies are reported with the inter-vial standard
deviation.
Cell culture
Human pancreatic adenocarcinoma cells (PANC-1) were
purchased from American Type Culture Collection
(ATCC, VA, USA) and cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin
(Sigma-Aldrich Co., MO, USA) at 37 °C and 5% CO2 at-
mosphere. For all experiments, cells between passages 5
and 24 were used. Cells were harvested using trypsin-
EDTA (Sigma-Aldrich Co., MO, USA) and counted
using a hemocytometer for use in sonoporation and via-
bility experiments.
Sonoporation of cells in suspension
PANC-1 cells (1.0 × 106 cells) were suspended in serum-
free DMEM containing PCCAs (8.5 × 108 particles) and
propidium iodide (PI, 30 μM) (Sigma-Aldrich Co., MO,
USA) for a final volume of 1.5 mL. PI was used as a
sonoporation indicator as it is impermeable to intact cell
membranes. The cell suspension was added to a custom
plastic cuvette with nearly acoustically transparent win-
dows made of 20-μm thick polyolefin film (Rajashrink,
Roissy, France) as previously described by Escoffre et al.
[23]. The cuvette was then held in a 37 °C degassed
water bath with constant magnetic stirring and posi-
tioned 5 cm in front of the transducer for sonoporation
treatment, as shown in Fig. 2.
To generate ultrasound pulses, a 1.0-MHz unfocused
piston transducer (diameter = 2.54 cm, IL0108HP, Valpey
Fisher Corp., Hopkinton, MA, USA) was excited by a
sinusoidal arbitrary function generator signal (AFG3021C,
Tektronix, Inc., Beaverton, OR, USA) amplified approxi-
mately 55 dB by an RF power amplifier (3100LA, ENI,
Rochester, NY, USA). The pressure output of the trans-
ducer at various excitation voltages was characterized
using a calibrated needle hydrophone placed 5 cm in front
of the transducer, matching the distance of the cuvette in
sonoporation experiments. The cell suspensions were
insonified for 30 s with peak negative pressures of 125,
300, or 600 kPa, pulse lengths of 5, 10, 20, or 50 cycles,
and a constant PRF of 5.0 kHz, as summarized in Table 1.
As controls, cells underwent (1) sham treatment (without
PCCAs or ultrasound exposure) and (2) ultrasound-only
treatment (without PCCAs) using the highest energy
condition—600 kPa and 50 cycles.
Post-treatment, cells were transferred to plastic tubes
and incubated at 37 °C for at least 15 min to ensure
membrane resealing processes were completed prior to
further manipulation of the cells [24]. Subsequently, the
viability stain calcein-AM (0.8 μM) (Thermo Fisher
Scientific Inc., MA, USA) was added and the cells were
allowed to incubate for at least an additional 30 min at
37 °C. Cells were filtered through a 44-μm nylon mesh
(Component Supply Co., FL, USA) before being analyzed
by flow cytometry. Cells showing both PI uptake and
calcein-AM cleavage by flow cytometry were considered
to be successfully sonoporated. These experiments were
repeated in triplicate on independent days. All sonopora-
tion conditions were also performed in triplicate without
the addition of dye to monitor changes in autofluores-
cence due to treatment.
Assessment of sonoporation efficiency by flow cytometry
Flow cytometry was used to quantify the number of
sonoporated cells for each treatment group, i.e., those
Fig. 2 Setup designed for the sonoporation of cells in suspension
with PCCAs
Table 1 Experimental and control conditions for sonoportion
Conditions PCCAs (Y/N) Cycles (#) PRF (kHz) Pressure (kPa)
1–4 Y 5, 10, 20, 50 5 125
5–8 Y 5, 10, 20, 50 5 300
9–12 Y 5, 10, 20, 50 5 600
US only control N 50 5 600
Sham control N NA NA NA
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cells displaying both PI uptake (permeabilization) and
calcein-AM cleavage (viability). An LSRFortessa cyt-
ometer equipped with 561- and 488-nm excitation lasers
(Becton Dickinson, Franklin Lakes, NJ, USA) was used
for acquisition, and 30,000 events were recorded for
each sonoporation treatment. For further details regard-
ing acquisition settings, please see Additional file 1:
Table S2.
The gating strategy employed to isolate sonoporated
cells is described in full in Additional file 1: Information
section and displayed in Additional file 2: Figure S1.
Briefly, singlet cells were isolated from debris and doub-
let cells through initial gating steps. The viability of the
chosen cell population was then confirmed by calcein
fluorescence. Curly quadrant gates were applied to the
calcein vs. PI fluorescence dot plots, with thresholds de-
termined such that unstained control cells would be
classified as both calcein and PI negative. The percent of
cells in quadrant two (calcein and PI positive) was taken
to be the sonoporation efficiency (i.e., percent of viable
cells that were sonoporated). All data analysis was per-
formed using FlowJo Data Analysis Software (FlowJo,
LLC., Ashland, OR, USA).
Assessing viability post-sonoporation treatment
Through our flow cytometry experiments, we found that
dead cells and cellular debris were characterized by ele-
vated autofluorescence in the calcein (viability) channel
(data not shown). Therefore, we were unable to accur-
ately quantify cell viability based on the flow cytometry
results alone. As such, we performed an additional cell
viability assay. Cells suspended in serum-supplemented
DMEM were subjected to the sonoporation protocol as
described above without the addition of PI or calcein-
AM. Following treatment, 1.0 × 105 cells per treatment
group were transferred to 24-well plates and allowed to
incubate for 24 h at 37 °C and 5% CO2 atmosphere. Sub-
sequently, cell viability was assessed using a resazurin-
based toxicology assay according to the manufacturer’s
protocol (Sigma-Aldrich Co., MO, USA).
Briefly, a volume of resazurin dye equal to 10% of the
culture media was added to the cells and allowed to in-
cubate for 3 h. A 200-μL sample from each culture well
was then transferred to a 96-well plate for analysis. The
fluorescence increase at 590 nm (F590) due to reduction
of the resazurin dye by viable cells was detected using a
plate reader (Synergy 2, BioTek Instrument, Inc.,
Winooski, VT, USA) with excitation and emission filters
of 530/25 nm and 590/35 nm, respectively. The fluores-
cence intensity of a blank sample containing complete
media but no cells was subtracted from that of each
sample. Cell viability was then calculated as the percent
resazurin reduction of the sham control. Viability experi-
ments were repeated in triplicate on independent days.
Statistical analyses
All statistical analyses were performed in GraphPad
Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA),
and data are presented as average ± standard deviation
throughout this work. Sonoporation efficiencies and cell
viabilities were compared among treatment groups using
one-way ANOVA followed by Dunnett’s multiple com-
parison testing on significant results. Each treatment
group was compared to the sham control, and p values
of <0.05 were considered statistically significant. Pearson
correlation coefficients (r) were computed in GraphPad
Prism 7 to analyze the correlation between (1) sonopora-
tion efficiency and stable cavitation and (2) sonoporation
efficiency and inertial cavitation. Correlations were con-
sidered statistically significant if the two-tailed p values
were <0.05.
Results
Detection of PCCA vaporization and subsequent
cavitation signals
Through optical high-speed microscopy and the detec-
tion of cavitation signals, we investigated the effect of
acoustic pulse length and peak negative pressure on
PCCA vaporization (a.k.a. acoustic droplet vaporization
(ADV)) and the behavior of resultant microbubbles. At a
frequency of 1.0 MHz, we found that our PCCAs
undergo ADV at and above peak negative pressures of
300 kPa but never at or below 125 kPa, regardless of
pulse length. This is consistent with previous reports
demonstrating that ADV is a pressure-dependent,
threshold phenomenon that is independent of pulse
length when short, microsecond pulses are used [25, 26].
Representative photos showing PCCAs before and after
ultrasound stimulation above and below the activation
threshold are displayed in Fig. 3a. Note that 300 kPa
does not represent an absolute pressure threshold for
vaporization; rather, we conclude that the vaporization
threshold is between 125 and 300 kPa under the condi-
tions studied.
While pulse length did not effect whether or not
vaporization would occur, it did influence the behavior
of resultant microbubbles. When generated microbub-
bles were stimulated with a second ultrasound pulse,
microbubble destruction occurred on a continuum. No
destruction was observed with low-pressure pulses
(300 kPa) and complete destruction of all microbubbles
in the field of view occurred with long pulses (20 and
50 cycles) at high pressure (1000 and 2000 kPa)
(Fig. 3b).
Microbubble sizes were estimated from the captured
images. Microbubbles generated from ADV at 300 kPa
were polydisperse and ranged in size between 2 and
10 μm. When the peak negative pressure was increased
to 600 kPa and above, generated microbubbles were
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observed in the 1- to 10-μm range; however, we note an
increase in the number of small (~1 μm) microbubbles
present. This is consistent with previous reports from
our laboratory detailing the dependence of generated
microbubble size on various acoustic parameters, includ-
ing peak negative pressure [27]. The shift towards
smaller resultant microbubbles with increased pressure
is due to the inverse relationship between vaporization
threshold and PCCA size [27, 28]. When generated
microbubbles were allowed to rest before being sub-
jected to a second acoustic pulse (Fig. 3b), we noticed
microbubble sizes shift to be larger (approximately
3–20 μm). This is likely due to coalescence of the
generated microbubbles.
The generation of stable and inertial cavitation signals
depended on peak negative pressure and pulse length.
Very little stable and no inertial cavitation was observed
at pressures of 125 kPa regardless of pulse length; the
slight stable cavitation may be due to oscillations of
microbubbles that arose from spontaneous vaporization.
Cavitation energy was observed from 300 to 2000 kPa,
with very little cavitation achieved with peak negative
pressures of 300 kPa and short (5 and 10 cycle) pulse
lengths (Fig. 4). The amount of stable cavitation pro-
duced reached a plateau between 24 and 29 dB for
50 cycle pulses with pressures between 300 and
2000 kPa. Alternatively, inertial cavitation continued to
increase with increasing pressure. Interestingly, the
Fig. 3 Observation of PCCA vaporization and secondary microbubble effects using high-speed photography. Representative photos are displayed
of PCCAs or resultant microbubbles before and after ultrasound stimulation (1.0 MHz center frequency). a The nanoscale, liquid-filled PCCAs are difficult
to observe before vaporization. A peak negative pressure of 125 kPa is not sufficient to vaporize the PCCAs (top). With a peak negative pressure of
300 kPa, efficient vaporization of the PCCAs into microbubbles is observed (bottom). b Secondary effects are observed when generated microbubbles
are subjected to a second acoustic pulse. At 300 kPa and 5 cycles, the second acoustic pulse appears to have no affect on the generated microbubbles
(top). With high acoustic energies, complete microbubble destruction is observed (bottom). Scale bar = 10 μm. a Vaporization b Secondary effects
Fig. 4 Quantification of the a stable and b inertial cavitation energy generated by PCCAs subjected to ultrasound of various peak negative
pressures and pulse lengths. Note: while error bars (SD) are plotted, they are not visible on all data points due to their small size. a Stable
Cavitation Detection b Inertial Caviatation Detection
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concentration of PCCAs did not significantly influence
the amount of stable or inertial cavitation detected (data
not shown), and obtained graphs for all tested concen-
trations were nearly identical to the one presented in
Fig. 4 for 0.67% (v/v) PCCAs in PBS.
Sonoporation efficiency
Flow cytometry was used to analyze the effect of acous-
tic pressure and pulse length on PCCA-facilitated PI up-
take through sonoporation. Dead cells were discarded
from the analysis through an initial gating step to re-
move cellular debris (Additional file 2: Figure S1). The
viability of remaining cells was confirmed using calcein-
AM staining. While the viability of gated cells was near
100% for all conditions, the percentage of cellular debris
was observed to increase with increasing acoustic en-
ergy, implying elevated cell death.
Sonoporation efficiency, the percent of viable cells dis-
playing PI fluorescence, was quantified as the percent of
cells in quadrant 2, as shown in Fig. 5. A small percent-
age of cells (2–4.5%) appeared in quadrant two for the
sham control, likely due to the prolonged exposure of
cells to PI. This was defined as the false positive rate and
was subtracted from the sonoporation efficiency of all
other treatment groups. The autofluorescence analysis
demonstrated slight spreading of unstained cell popula-
tions along the PI axis due to ultrasound treatment with
PCCAs (Additional file 3: Figure S2). The average
percent of cells classified as PI positive due to autofluo-
rescence never exceeded 2%, but these values were sub-
tracted from the final sonoporation efficiencies of all
groups.
Statistically significant elevation in PI uptake was ob-
served at 300 kPa with pulse lengths of 20 and 50 cycles
and at 600 kPa with 5–50 cycle pulse lengths compared
to the sham control. Sonoporation efficiency increased
with peak negative pressure and pulse length, reaching a
maximum of 36 ± 4% at 600 kPa and 50 cycles (Fig. 6).
As expected, we did not observe sonoporation below the
vaporization threshold of the PCCAs (i.e., at 125 kPa) or
when cells were insonified in the absence of PCCAs.
Cell viability 24 h post-treatment
To test the effect of sonoporation treatment on cell via-
bility, cells were treated using a protocol identical to that
employed for sonoporation but without the addition of
Fig. 5 Representative flow cytometry dot plots used to quantify sonoporation efficiency. Cells were classified as sonoporated if they showed
calcein fluorescence (viability) and uptake propidium iodide (membrane permeability). These cells appear in quadrant 2 (Q2) in the dot plots.
a The small percentage of cells that appear in Q2 for the sham treatment group was defined as the false positive rate and was subtracted from
the percent of cells in Q2 for all treatment groups. b Ultrasound exposure below the PCCA activation threshold did not result in sonoporation.
c, d Sonoporation is observed above the PCCA activation threshold and increases with increasing pressure. a Sham Control b 125 kPa - 20 cycles
c 300 kPa - 20 cycles d 600 kPa - 20 cycles
Fix et al. Journal of Therapeutic Ultrasound  (2017) 5:7 Page 7 of 11
PI or calcein-AM. Twenty-four hours post-treatment,
viability was assessed using a resazurin-based metabolic
assay. Ultrasound exposure in the absence of PCCAs did
not affect cell viability. Furthermore, the PCCAs them-
selves did not have a toxic effect on cells as evidenced
by the high viability in treatment groups below the
PCCA activation threshold (i.e., 125 kPa treatment
groups). We did observe decreasing cell viability with in-
creasing cycle number and pressure above the activation
threshold. In general, fairly high viability was recorded
for those cells treated with 300 kPa ultrasound of vari-
ous pulse lengths (84 ± 7%–94 ± 7% viability) and cells
treated with 600 kPa ultrasound with pulse lengths
between 5 and 20 cycles (85 ± 12%–93 ± 6%) (Fig. 7). A
statistically significant drop in viability (70 ± 5%) was
observed in cells treated with 600 kPa and 50 cycles
compared to sham treated cells.
Discussion
Acoustic or temperature-induced droplet vaporization
can be achieved without membrane perforation or
impaired cell viability
Our PCCAs are comprised of a very low-boiling point PFC
and undergo some spontaneous vaporization when incu-
bated at 37 °C. Therefore, cells incubated with PCCAs and
exposed to ultrasound below the activation threshold (i.e.,
at 125 kPa) felt the effects of temperature-induced
vaporization alone. The membrane permeability and viabil-
ity of cells treated in this way was unaltered. Additionally,
cells treated with PCCAs at 300 kPa with pulse lengths of
5 or 10 cycles demonstrated insignificant sonoporation effi-
ciencies and no change in cell viability. These cells were
exposed to acoustic droplet vaporization but minimal cavi-
tation of the resultant microbubbles. These data indicate
that vaporization events do not affect cellular membrane
permeability or cause any detrimental cellular bioeffects.
This is in contrast to the bioeffects observed following
the vaporization of micron-sized, DDFP-filled PCCAs
used for vascular occlusion. Seda, et al. have demonstrated
that vaporization of DDFP-filled droplets results in exten-
sive cell death even when using acoustic parameters de-
signed to minimize secondary mechanical effects from the
resultant bubbles [29]. Differences in experimental setups
(cells treated in adherent culture vs. in suspension) and
size distributions of PCCAs (1.6 ± 0.5 μm vs. 143 ± 13 nm
mean size) make it difficult to directly compare these re-
sults. However, the difference in severity of bioeffects ob-
served is likely due to the difference in pressure required
to vaporize the PCCAs. Rarefactional pressures of at least
6 MPa were required for vaporization of DDFP-filled
PCCAs, while 300 kPa was sufficient for vaporization of
our PCCAs. By using a highly volatile formulation with
lower pressure requirements for ADV, we can safely in-
duce vaporization without immediately and irreparably
damaging surrounding cells.
PCCA-induced sonoporation is correlated with stable and
inertial cavitation
Sonoporation efficiency was found to be significantly
and positively correlated with both stable (r = 0.9352,
Fig. 6 Sonoporation efficiency of PANC-1 cells at various acoustic
pressures and pulse lengths. As expected, we do not observe
sonoporation below the vaporization threshold of the PCCAs (i.e., at
125 kPa) or when cells are insonified in the absence of PCCAs (US
alone). One-way ANOVA was used followed by Dunnett’s multiple
comparisons test compare each treatment to the sham control.
*p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001
Fig. 7 Cell viability 24 h post-sonoporation treatment. Here, we
observe decreasing cell viability with increasing pulse length and
pressure. As expected, ultrasound exposure in the absence of PCCAs
does not affect cell viability. Furthermore, the PCCAs themselves did
not have a toxic effect on cells as evidenced by the high viability in
treatment groups below the PCCA activation threshold (i.e., 125 kPa
groups). One-way ANOVA was used followed by Dunnett’s multiple
comparisons test to compare each treatment to the sham
control. ***p ≤ 0.001
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p < 0.0001) and inertial (r = 0.9456, p < 0.0001) cavitation
(Fig. 8). While it is difficult to ascertain a cavitation
threshold for sonoporation from these data, we note that
all statistically significant sonoporation treatments were
associated with stable cavitation energies greater than
7.9 dB and inertial cavitation energies greater than 5.2 dB.
This study was not designed to elucidate the mechanisms
driving PCCA-mediated sonoporation, but our data sug-
gest that the mechanical effects due to microbubble-
ultrasound interactions are necessary for significant
sonoporation. Therefore, it is likely that the same mecha-
nisms that drive conventional microbubble-mediated
sonoporation also drive PCCA-mediated sonoporation.
The peak sonoporation efficiency we achieved (36%) is
similar to what has previously been reported for micro-
bubble sonoporation (28–39% efficiency) [6, 30, 31], al-
beit with lower cell viability (70% viability for PCCA
sonoporation vs. 90–96% viability for MB sonoporation
[6, 30, 31]). However, these microbubble sonoporation
studies employ unique strategies to increase sono-
poration efficiency and minimize cell death, making it
difficult to make direct comparisons. For example,
McLaughlan et al. achieved their highest viable sono-
poration using a combination of (1) targeted microbub-
bles that increase cell-microbubble interactions and (2)
chirp frequency excitation to maximize the response of
their polydisperse microbubbles [6]. Song et al. found
that using monodisperse 2.0-μm microbubbles resulted
in the highest sonoporation and viability after a single
ultrasound treatment [31]. We believe that with further
optimization of our PCCA-mediated sonoporation
methods, we will be able to match the sonoporation
efficiencies and viabilities achieved with microbubbles. Fu-
ture studies will be designed to apply the aforementioned
techniques developed by the microbubble sonoporation
community to PCCA-mediated sonoporation.
Conclusions
In conclusion, our data show that low-boiling point PCCAs
are capable of inducing sonoporation without causing detri-
mental cellular bioeffects in vitro. Furthermore, the low
pressure required to activate such PCCAs allows us to fine-
tune the severity of cellular bioeffects simply by modifying
pulse length. This provides flexibility in future applications
imaginable and allows for acoustic droplet vaporization to
be achieved safely and with existing diagnostic imaging
hardware. Here we demonstrate the ability to cause (1)
vaporization with no cellular damage—ideal for diagnostic
imaging applications, (2) reversible sonoporation—desirable
for therapeutic applications such as drug or gene delivery
where cell death is to be avoided, or (3) irreversible sono-
poration—useful in augmenting tumor killing through
high-intensity focused ultrasound treatment.
A limitation of this study is that we did not control for
differences in PCCA vaporization efficiency at each
acoustic condition. In other words, more bubbles were
likely generated using the highest energy conditions
compared to the lowest energy conditions as a constant
PCCA concentration was used throughout. This makes
it difficult to draw conclusions about sonoporation
mechanism and parameter optimization. The increases
in sonoporation efficiency with increasing pressure and
pulse length may have been due to (1) increased cavita-
tion and associated mechanical effects, (2) increased
concentration of generated microbubbles, or (3) a com-
bination thereof. Future studies will be designed to
quantify the vaporization efficiency of PCCAs at each
acoustic condition to allow for concentration matching
a b
Fig. 8 We observe a strong, positive correlation between sonoporation efficiency and a stable cavitation and b inertial cavitation. The Pearson
correlation coefficients for sonoporation efficiency vs. stable and inertial cavitation are 0.9352 and 0.9456, respectively, and both correlations are
statistically significant with p values <0.0001. Data points corresponding to statistically significant sonoporation efficiencies (compared to sham
control) are shown in red circles, while data points corresponding to statistically insignificant sonoporation efficiencies are shown in blue squares. a
Stable Cavitation b Inertial Caviation
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of generated microbubbles. Other important parameters
to consider are contrast agent size distribution, ultra-
sound exposure duration, and center frequency. Future
studies will be designed to optimize these parameters
and provide a thorough comparison between the sono-
poration potential of microbubbles, low-boiling point
PCCAs, and high-boiling point PCCAs.
One of the main advantages of using PCCAs for re-
versible sonoporation compared to microbubbles is the
potential for their extravasation from a tumor’s leaky
vasculature. While we note that the mean size of our
PCCAs is smaller than the pore sizes in many permeable
tumor lines (200–1.2 μm) [32], the extravasation and ac-
cumulation of our particles in tumors has yet to be con-
firmed. Studies are currently ongoing towards this end.
Nevertheless, our data warrant further investigation into
the use of PCCAs to induce extravascular sonoporation
in vivo for the purpose of enhancing local drug or gene
delivery, particularly within solid tumors.
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